MannKind rises as FDA updates label for inhaled insulin Afrezza

Shares of drugmaker MannKind MNKD.O rise 8% to $5.89 premarket

Co says U.S. FDA approved a new label for its inhaled insulin product, Afrezza, used at mealtime to control blood sugar in adults with diabetes

Co says update gives doctors clearer steps on how to switch patients from injected insulin to the inhaled version

MNKD's Afrezza is taken through a small inhaler at the start of meals, per co

Studies cited by co show improved control of after‑meal blood sugar spikes - MNKD

Co says Afrezza should not be used by people with asthma, COPD or smokers due to breathing-related risks

Most common side effects include low blood sugar, cough and throat irritation, co says

Shares down ~12% in 2025